Cefepime for Citrobacter koseri UTI
Yes, cefepime is effective for treating urinary tract infections caused by Citrobacter koseri, as it is FDA-approved for both uncomplicated and complicated UTIs and has demonstrated excellent clinical and microbiological efficacy against gram-negative organisms including Citrobacter species. 1
Rationale for Use
Cefepime is a fourth-generation cephalosporin with FDA approval specifically for uncomplicated and complicated urinary tract infections 1. The drug achieves adequate urinary concentrations and provides reliable activity against common gram-negative pathogens, including Citrobacter species which fall within the Enterobacterales family 2.
Clinical Evidence Supporting Efficacy
The evidence base for cefepime in UTIs is robust:
- Clinical cure rates of 89-92% and bacterial eradication rates of 85-92% have been demonstrated in both complicated and uncomplicated UTIs 3
- In a large evaluation of 204 hospitalized patients with various bacterial infections including UTIs, cefepime achieved a 94% clinical cure rate and 93% pathogen eradication 4
- Cefepime has proven effective even in complicated UTIs with concurrent bacteremia, achieving 97% clinical cure in these severe cases 4
Citrobacter koseri Considerations
Citrobacter koseri is an Enterobacterales species that typically produces inducible chromosomal AmpC β-lactamases. Recent meta-analysis data from 2025 demonstrates that cefepime performs comparably to carbapenems for AmpC-producing Enterobacterales bloodstream infections, with no significant difference in mortality or relapse rates 5. This is particularly relevant since Citrobacter species are AmpC producers.
Dosing Recommendations
For UTIs caused by Citrobacter koseri:
- Standard dosing: 500 mg IV/IM every 12 hours for uncomplicated UTI
- Complicated UTI or pyelonephritis: 1-2 g IV every 8-12 hours
- Treatment duration: 7 days for complicated UTI; up to 14 days if bacteremia present or in men when prostatitis cannot be excluded 6
Critical Dosing Adjustments
Renal function monitoring is mandatory - cefepime is substantially excreted by the kidney, and dose adjustment is required when creatinine clearance ≤60 mL/min 1. Failure to adjust dosing in renal impairment can lead to serious neurotoxicity including encephalopathy, myoclonus, and seizures, particularly in elderly patients 1.
Carbapenem-Sparing Strategy
Cefepime serves as an excellent carbapenem-sparing agent for Citrobacter koseri UTIs. Multiple studies confirm comparable efficacy to carbapenems while preserving these critical drugs for more resistant organisms 7, 8. In a 2018 study specifically examining UTIs, cefepime showed zero clinical or microbiological failures compared to carbapenems 7.
Important Caveats
- Always obtain urine culture and susceptibility testing to confirm activity against the specific isolate 6
- Consider local resistance patterns when selecting empirical therapy 2
- For patients with catheter-associated UTI, ensure true infection rather than asymptomatic bacteriuria before treating 2
- Monitor for neurological adverse effects, especially in elderly patients or those with renal impairment 1